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Surfactant protein D (SP-D) is a multimeric collagenous lectin that mediates the clearance of pathogens and modulates immune cell
functions via its C-terminal carbohydrate recognition domain (CRD). We hypothesized that extracellular proteolysis of SP-D may result in a
loss of its functional properties. Multimeric SP-D was partially digested by human leukocyte elastase (HLE) dose- and time-dependently.
Physiologic concentrations of calcium slowed, but did not protect from degradation. In solution, both native and degraded SP-D had an
apparent molecular weight of 650 to >1000 kDa. Under reducing conditions, the degraded SP-D monomers run at 10 kDa less than native SP-
D. Amino acid sequencing located all major cleavage sites into the CRD. Functional studies showed that degraded SP-D had lost its calcium-
dependent lectin properties, i.e. neither bound to mannose nor agglutinated bacteria. These studies demonstrate that elastase results in the
limited proteolysis of SP-D with loss of its CRD-dependent activities and suggest that proteases at concentrations observed in various lung
diseases may impair the antimicrobial and immunomodulatory roles of SP-D.D 2003 Elsevier Science B.V. All rights reserved.Keywords: Surfactant protein D; Human leukocyte elastase; Serine protease; Cystic fibrosis; Bronchiectasis; Innate and adaptive immune system1. Introduction
Surfactant protein D (SP-D) is a member of collagenous
host defense lectins called collectins [1]. SP-D is secreted
into the distal airspaces of the lung [2,3], but is expressed
also in other tissues [4,5]. SP-D is predominantly assembled
as dodecamers, consisting of four homotrimeric subunits
(12 = 4 3 chains). Each trimeric subunit consists of three
similar monomers (molecular weight (MW) 43 kDa) and
contains four major domains. A short N-terminal, cysteine-
containing cross-linking domain, a triple helical collagen
domain, a coiled-coil linking domain and a carboxy-termi-
nal, C-type lectin carbohydrate recognition domain (CRD)
[6]. The collagen-domain is post-translationally O- and N-
linked glycosylated causing some heterogeneity of the SP-D
monomers [7]. SP-D dodecamers can self-associate at the
amino termini to form highly ordered multimers as shown0925-4439/03/$ - see front matter D 2003 Elsevier Science B.V. All rights reserv
doi:10.1016/S0925-4439(03)00063-2
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E-mail address: mgriese@helios.med.uni-muenchen.de (M. Griese).for SP-D from human pulmonary alveolar proteinosis (PAP)
patients.
The CRD shows specific interactions with various micro-
organisms including viruses, bacteria and fungi [6] as well
as with leukocytes and phagocytes. SP-D binds to the
glycoconjugates expressed by Gram-negative bacteria
including Pseudomonas aeruginosa in a calcium-dependent
manner. This binding results in microscopic or macroscopic
aggregation of the bacteria and may enhance their elimi-
nation from the lungs by an improved presentation of these
microorganisms to defense cells [6,8].
Alveolar macrophages are possibly involved in the
removal of SP-D from the airspace, since SP-D has been
found in endosomal vesicles and lysosomes of those cells
[6] and in vitro, cell-associated macrophage proteases
rapidly degrade SP-D [9]. However, little is known about
the extracellular degradation of SP-D. Interestingly, in a
previous study, dodecamers of recombinant rat SP-D were
not degraded by human leukocyte elastase (HLE) or a
variety of secreted mammalian neutral proteases at 37 jC
in the presence of physiologic calcium concentrations
[10]. This observed resistance of SP-D to proteolyticed.
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even if other components have already been compromised
[10]. Free, unopposed proteases have been observed in
many chronic inflammatory lung diseases, e.g. in cystic
fibrosis [11,12], chronic obstructive lung disease [13],
chronic lung disease of prematurity [14], leading to
progressive destruction of pulmonary structural defense
and regulatory proteins. Therefore, it is of great interest
to analyze the propensity of human SP-D including its
biological activity to proteolysis in more detail.
Thus, the goal of this study was to investigate the
susceptibility of SP-D to proteolytic attack by HLE and to
characterize the potential impacts on its functions.2. Materials and methods
2.1. Preparation of the human SP-D
Native SP-D was isolated by affinity chromatography
from bronchoalveolar lavage (BAL) fluid from PAP
patients undergoing therapeutic BAL [15]. Briefly, the
lavages were made 10 mM with respect to EDTA and
centrifuged at 2000 g. The resulting supernatant was
recalcificated by addition of 35 mM CaCl2, the pH was
adjusted to 7.4 and mixed with equilibrated maltose
agarose (Sigma, Deisenhofen, Germany; 20 mM Tris–
HCl, 10 mM CaCl2, 0.02% sodium azide, pH 7.4). After
packing on a column, the SP-D was eluted with 20 mM
Tris, 100 mM MnCl2, pH 7.4. The final purification was
reached by gel filtration. A Superose 6 column (300 10
mm, Amersham Pharmacia Biotech, Uppsala, Sweden)
was equilibrated with 150 mM NaCl, 20 mM Tris–
HCl, 5 mM EDTA, pH 7.4 using the A¨kta apparatus
(Pharmacia, Uppsala, Sweden). The column was eluted at
0.5 ml/min, the void volume of the column was 7 ml.
One-milliliter fractions were collected and aliquots were
analyzed by SDS electrophoresis. The column was cali-
brated with blue dextran (2000 kDa), thyreoglobulin (669
kDa), apoferritin (443 kDa), holo-transferrin (77 kDa),
ovalbumin (45 kDa) and lysozyme (14 kDa) (Sigma).
2.2. Exposure of the SP-D to HLE
SP-D (100 ng/ml) was incubated with HLE (5 U/ml;
50 U/ml, E.C. 3.4.21.37, 875 U/mg protein, 1 U was
equal to 0.04 nmol of the enzyme, molecular weight 29.5
kDa) (Elastin Products, Owensville, MO, USA) dissolved
in 50 mM Tris–HCl pH 6.5, 150 mM NaCl, 0.01%
sodium azide (w/v) in a final volume of 200 Al. Using a
molecular weight of 12 43 kDa, i.e. 516 kDa, for the
SP-D duodecamers, in the incubations there was about a
1000-fold excess of HLE on a molar basis. The experi-
ments were prepared in 1.5-ml plastic tubes on ice,
started by the addition of the protease and followed by
the various incubation periods at 37 jC. The reactionswere stopped by the addition of 5 mM phenylmethylsul-
fonylfluoride (PMSF) and immediately frozen at  70 jC
until assayed. All experiments were also done in the
presence of 2 mM CaCl2. As negative control, SP-D was
also incubated for 240 min at 37 jC in buffer only or
with heat inactivated HLE (95 jC, 30 min) or together
with 5 mM PMSF. All incubations contained in addition
0.125 mM EDTA, 0.5 mM Tris–HCl and 3.75 mM
NaCl, resulting from the SP-D stock solution. All experi-
ments were reproduced at least three times.
2.3. SDS electrophoresis and Western blotting
The freeze-dried samples were reconstituted and run
under reducing conditions on NuPAGE 10% Bis–Tris gels
using the NuPAGE–MOPS–SDS running buffer and the
NOVEX X-cell II Mini-Cell system (Novex, San Diego,
CA, USA). For nonreducing conditions, NuPAGE Tris–
Acetate 3–8% gels with the NuPAGE–Tris–Acetate SDS
running buffer were used. Mark 12k Wide-Range or See-
Bluek prestained marker and ovalbumin (45 kDa) served
as molecular weight standards. Gels were silver stained
(Novex SilverXpress-Silver-Staining-Kit) or proteins were
transferred onto nitrocellulose or PVDF membranes (Amer-
sham Pharmacia Biotech) for semi-dry Western blotting
using the NOVEX X-cell Blot module (Novex). SP-D was
identified with a specific polyclonal antibody to human SP-
D (1:250) (gift of Prof. KBM Reid, Oxford, UK). For
comparison, recombinant rat and human SP-D was used
(gift of Prof. E. Crouch, Department of Pathology, Wash-
ington University, St. Louis, MO, USA). Enhanced chem-
iluminescence assay (Amersham Life Science, Amersham,
Buckinghamshire, UK) with horseradish-peroxidase-conju-
gated goat anti-rabbit polyclonal IgG (1:10000; Sigma) as
second antibody was used for detection. Silver-stained gels
and blots were scanned with a computing densitometer
(Fluor-S MultiImager System, BioRad, Richmond, CA,
USA) and image analysis was carried out using the Multi-
Analyst software (BioRad).
2.4. N-terminal sequence analysis
Four micrograms of SP-D was incubated for 240 min
at 37 jC with 5 U/ml HLE in a final volume of 4 ml.
This incubation also contained 37.5 mM NaCl, 5 mM
Tris–HCl and 1.25 mM EDTA. An aliquot was used for
SDS-electrophoresis under reducing conditions, blotted on
PVDF membranes, stained by NOVEX-Colloidal-Blue Kit
(Novex) and also identified by Western blotting as
described above. Another aliquot was submitted to
Edman degradation using the sequencer Procise 492 and
the On-Line PTH Analyzer 140 C (Biosystems, Weiter-
stadt, Germany). N-terminal sequences of the SP-D frag-
ments were compared with the known sequence of
human SP-D (SWISS PROT database) and allocated to
the different parts of the protein.
Fig. 1. SDS-PAGE (10%) under reducing conditions. Lanes 1–4, silver stain; lanes 5–17, immunoblots using a polyclonal anti-human SP-D antibody. For
each single experiment, 100 ng of SP-D was applied. Lane 1: 500 ng of ovalbumin (45 kDa) as a globular protein standard for comparison in addition to the
molecular weight standards indicated at the left and right margin. SP-D was incubated with HLE (5 U/ml) for the indicated time periods in the presence (2 mM)
or absence of calcium and the serine protease inhibitor PMSF in a final volume of 200 Al. The data shown are representative of three independent experiments.
Fig. 2. SDS-PAGE (10%) under reducing conditions and immunoblot using
a polyclonal anti-human SP-D antibody. For each single experiment, 100 ng
of SP-D was applied. The SP-D was incubated in a final volume of 200 Al
for 240 min, in the absence of calcium, without HLE or with 5 or 50 U/ml.
Lanes 1–3, recombinant human SP-D; lanes 4–6, SP-D isolated from a
patient with PAP; and lanes 7–9, recombinant rat SP-D. The molecular
weight standards are indicated at the left and right margins. The data shown
are one of two independent experiments.
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For the assessment of the binding capacity of SP-D to
sugar surfaces, the microtiter plates were coated with 20
Ag/ml avidin overnight at 4 jC (ICN, Aurora, OH, USA)
in carbonate-buffer (15 mM Na2CO3, 35 mM NaHCO3,
pH 9.6), followed by the addition of 2 Ag/ml a-D-maltose-
PAA biotin for 1 h at 37 jC (Syntesome, Moscow,
Russia). After washing, the plates were blocked with
phosphate-buffered saline (17.9 mM KH2PO4, 75 mM
NaCl, 56 mM Na2HPO4, pH 7.4), 1% gelatine (E. Merck,
Darmstadt, Germany) and 0.1% NaN3 for 4 h at room
temperature and washed with 50 mM Tris–HCl, 150 mM
NaCl, 2 mM CaCl2, pH 7.4. After incubation for 3 h with
the various samples of SP-D in the presence and absence
of EDTA (10 mM), bound SP-D was cross linked using
0.125% glutaraldehyde, the plates were blocked again and
bound SP-D was quantified by the polyclonal anti-SP-D
antibody, which was detected by avidin–peroxidase com-
plex (DAKO, Glostrup, Denmark). Color was generated
with ABTS (Boehringer-Mannheim, Mannheim, Germany)
and H2O2 and read at 405 nm. All assays were run in
duplicate.
2.6. Agglutination of P. aeruginosa by SP-D
A clinical isolate of P. aeruginosa (Ps 12, nonmucoid,
from a patient with cystic fibrosis), previously selected for
Ca2 + and carbohydrate-dependent agglutination, was
washed three times in 50 mM Tris–HCl, 150 mM NaCl,
pH 7.4, resuspended in the same buffer with 2 mM CaCl2,
and incubated on glass cover slides with the different SP-D
preparations (1 Ag SP-D incubated with or without 1 U of
HLE or solvent in a final volume of 200 Al), in the absence
and presence of 10 mM EDTA or 50 mM maltose. After 4
min, the slides were viewed under the microscope and
photographs were taken. In another set of experiments, PS12 was agglutinated with SP-D (1 Ag in a final volume of
200 Al) and after 2 min HLE (1U) or its solvent was added
and incubated for another 5 min, 1, 2 and 24 h at 37 jC, in
order to investigate an effect of the HLE on the stability of
the agglutinated bacteria.3. Results
The SP-D used throughout this study was purified from a
patient with PAP to more than 99% homogeneity, as judged
by Coomassie blue staining (not shown), silver staining
(Fig. 1, lane 4) and immunoblotting (Fig. 1, lane 5). Under
reducing conditions in 10% Bis–Tris SDS, SP-D ran at 47–
51 kDa, similar to recombinant rat and recombinant human
Fig. 3. SDS-PAGE (3–8%) under nonreducing, denaturing conditions,
Western blotting followed by the polyclonal SP-D antibody. SP-D was
incubated at a molar ratio of 1:5 with HLE (5 U/ml) in the absence of
calcium for the indicated time periods, without (lanes 1–4) and with (lanes
5–7) the serine protease– inhibitor PMSF. The data shown are representa-
tive of two independent experiments.
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proteins previously, under the conditions used throughout
this study the native and all recombinant SP-D migrated at aFig. 4. Gel chromatography of native SP-D. SP-D, before and after HLE treatment
6.5, 187.5 mM NaCl, 1.25 mM EDTA for 240 min) was applied to a Superose-
column was calibrated under identical conditions, using blue dextran, thyreoglo
fractions were separated under reducing conditions (10% SDS gels), transferred
(representative of three experiments).position approximately 5–6 kDa higher than observed in
previous studies with other buffer and gel systems [15–17].
HLE readily and time-dependently degraded the SP-D in
the absence of calcium to a fragment(s) of about 38 kDa
(Fig. 1, lanes 9–13), i.e. 10 kDa less than the original
material. This fragment was apparently not further cleaved
despite prolonged and more intense (50 U/ml) exposure to
the enzyme. Whereas sometimes dimers or trimers of the
fragment(s) were noted (Fig. 1, lanes 11 and 12), lower
molecular weight cleavage products were not detected by
immunoblotting. The presence of the serine protease inhib-
itor PMSF (Fig. 1, lanes 14–17) or previous denaturation of
the HLE by boiling for 10 min (date not shown) completely
blocked proteolysis.
The presence of calcium substantially delayed the degra-
dation of SP-D, i.e. after 4 h of exposure to 5 UHLE/ml, there
was only little degradation (Fig. 1, lane 8), and at 0.5 U HLE/
ml, no degradation could be detected (not shown). With 50 U
HLE/ml and no calcium, a similar pattern of degradation was
observed as at 5 U HLE/ml in the presence of calcium. Even
in the presence of calcium, 50 U HLE/ml partially degraded
more than 70% of the SP-D after 10 min (not shown).
In the absence of calcium and at 50 U/ml of HLE, the
degradation of the SP-D occurred irrespective of its source,
i.e. human recombinant SP-D, human alveolar proteinosis
SP-D, as used throughout this study, or rat recombinant SP-D
(Fig. 2). However, at 5 U/ml of HLE, the human recombinant(4 Ag of SP-D, 5 U HLE/ml, final volume of 4 ml of 55 mM Tris–HCl pH
6 column. No differences in elution profile were noted (upper panel). The
bulin, apoferritin, holo-transferrin, ovalbumin and lysozyme. All column
to a PVDF membrane and probed with a polyclonal anti-SP-D antibody
Fig. 5. Dose-dependent binding of SP-D to maltose-coated to the surface of
microtiter plates. This binding was completely inhibited by preincubation of
the SP-D with HLE (5 U/ml, 240 min), or by the presence of 50 mM free
maltose, 10 mM EDTA in a final volume of 200 Al (not shown). The
presence of the serine protease inhibitor PMSF during HLE incubation
completely inhibited the HLE effect on SP-D.
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intensities of the traces on the blot may be related to differ-
ences in the amounts (compare also to Fig. 1, lanes 1–3) and
the immunoreactivity of the three preparations used (Fig. 2).
Under nonreducing, but denaturing, conditions in Tris–
Acetate 3–8% SDS gels, the majority of the SP-D gave one
band at the apparent molecular weight of 138 kDa. This is
consistent with the presence of trimers. Some of the SP-D
run at about 280–420 kDa, suggesting higher molecular
assembles, i.e. two or three sets of trimers (Fig. 3). Proteol-
ysis by HLE generated a single fragment of about 108 kDa,
i.e. 30 kDa less than the native SP-D (Fig. 3, lanes 3 and 4).
This is consistent with the previously observed cleavage of
SP-D monomers leading to a MW loss of 10 kDa under
reducing conditions, whereas trimers of SP-D lost 30 kDa
after treatment with HLE (Fig. 1). Without denaturation, the
protein did not enter the SDS gels (not shown).
The native, nonreduced and nondenatured SP-D was
therefore studied by gel-chromatography in the absence of
calcium. SP-D eluted in the fractions 6 to 9, corresponding
to a molecular weight between >1000 and 670 kDa (Fig. 4,
upper panel, left). This is consistent with the presence of
dodecamers and higher-ordered multimers, as expected for
SP-D from alveolar proteinosis patients. Smaller fragments
(670–20 kDa) were not detected at 280 nm or other wave-
lengths. All fractions separated by gel filtration were run
under reducing conditions on SDS gels followed by Western
blotting. In the fractions containing SP-D, again a loss of 10
kDa was observed after HLE treatment (Fig. 4, lower
panels). These data suggest that the degraded SP-D stays
assembled in multimers, although each of its monomeric
constituents was truncated by about 10 kDa.
N-terminal amino acid sequencing was performed to
identify the cleavage sites in the SP-D. Due to a blocked
N-terminus in the native SP-D chain, no sequence data were
obtained of the full-length polypeptide chain. The N-termi-
nal blockade has also been reported by others [16,18].Table 1
Sequence analysis of the fragments generated from human SP-D by human leuko
Estimated
relative amount
(percent of total)
Fragments generated by the human leukocyte
elastase and identified by sequencing from
the newly generated NV-terminus
Amino acid sequence
of the fragment
identified
(Swiss-Prot. P35247)b
MW (kDa)
of the fragmen
through to the
C-terminus, i.e
position Phe375
Fragment 1 42 Tyr334–Ser348 5
Fragment 2 42 Phe312–Thr328 7
Fragment 3 12c Gln278–Ser290 10
Fragment 4 2 Glu252–Glu262 13
Fragment 5 2c Gln132–Glu146 25
a See also Fig. 1, lane 11.
b Amino acid sequence was identical to the one expected for the respective fr
c Estimate of the amount present may be too low, due to formation of pyrogluta
the mixture (IVGGRRARPHAW), however, only in minor amounts.However, as the HLE generated new N-termini, three major
fragments were identified (Table 1). All cleavage sites were
characteristic for the serine protease used and were located
in the C-terminal globular CRD of SP-D (Leu279 through
Phe375). The small fragments generated were between an
estimated molecular weight of 5–10 kDa and were not
identified on the gels by immunoblotting, as described
above. The calculated molecular weights of the remaining
complementary larger fragments were between 33 and 46
kDa. This is in accordance with the size of the immunor-
eactive proteolytic fragments of SP-D detected in our
experiments (Table 1).
An impaired CRD should be associated with a loss or
reduction of its functions. This was demonstrated by a
complete loss of the binding capacity of SP-D to maltose-
coated surfaces after exposure to HLE (Fig. 5). The immu-cyte elastase
Complementary fragments not identified
due to the blocked N-terminus in the
native SP-D chain
Observed sizes of the
proteolytic fragments
on the gela (kDa)
t
.
Calculated MW (kDa) [MW of SP-D
(average 48, range 43–51 kDa) minus
MW of the fragment in the column to
the left]
43 (38–46)
41 (36–44)
38 (33–41) mean 38 (34–42)
35 (30–38)
23 (18–26)
agments in SP-D and is detailed at http://www.expasy.ch.
mate at a N-terminal Gln278. Human leukocyte elastase was also identified in
Fig. 6. The gram-negative bacteria P. aeruginosa were dose-dependently
agglutinated by SP-D in the presence of calcium. Note the aggregates of the
bacteria in the upper panel. This effect was dependent on the lectin-binding
properties of SP-D and was inhibited by free maltose and chelation of the
calcium (data not shown). After incubation of the SP-D with HLE (5 U/ml,
240 min) in a final volume of 200 Al, no agglutination of the bacteria was
observed, indicating the functional inactivation of the SP-D.
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detected, but did not bind to the carbohydrate anymore. In
addition, the ability to agglutinate P. aeruginosa by native
SP-D was lost after exposure to the protease HLE (Fig. 6). In
another set of experiments, P. aeruginosa was agglutinated
with SP-D and then incubated for up to 24 h at 37 jC with
HLE, to investigate an effect of the HLE on the stability of the
agglutinated bacteria. No effect on the disruption of the
aggregates was observed (n = 4, data not shown).4. Discussion
HLE can attack native SP-D dodecamers and higher-
structured multimers and digests their C-terminal CRDs.
The resulting cleavage products are functionally inactive
with respect to calcium-dependent lectin properties, i.e.
binding to mannose and agglutination of bacteria.
The partially degraded SP-D and the native SP-D eluted
both at an apparent molecular weight of >1000–670 kDa as
assessed by gel chromatography. Anyway, this method wasnot sufficient at the molecular weight range of interest to
resolve changes in the molecular weight of SP-D multimers
after damage to HLE, i.e. of about 120 kDa (12 10 kDa)
as expected for SP-D dodecamers. In contrast, with com-
plete denaturation and reduction of the molecule, there was
a 10-kDa difference between the native and the cleaved
immunoreactive SP-D monomers on SDS-gels. Under dena-
turing but nonreducing conditions, a trimeric species of SP-
D was observed. Under these conditions, the 30-kDa differ-
ence in size between the native and proteolytic species was
consistent with the 10-kDa size difference observed for the
monomers. There are numerous theoretical cleavage sites
for HLE in all different domains of SP-D. These results,
together with the sequence data, which localize the sites for
proteolysis to the CRD, are in agreement with the concept
that the HLE mainly has access to those parts of the SP-D
multimers that are located at the margins of the protein
complex. Steric hindrance of protease binding near the
central N-terminal hub or to the collagenous domain may
be responsible for the remarkable insensitivity of these
domains to proteolytic damage by HLE. In contrast, the
CRD has defined conformational folds for calcium binding
that may cooperatively alter its overall steric orientation.
These calcium ions are invariably needed for the interaction
of SP-D with the specific carbohydrates. Notably, the
presence of calcium significantly slowed the time course
of proteolysis of SP-D and also shifted the dose–response
curve to higher concentrations of HLE. These data are in
consent with the hypothesis that changes of the conforma-
tion of the CRD are induced by physiologic concentrations
of calcium and are protective against the proteolytic attack
of elastase. Alternatively, or in addition, divalent cations
may modify the molecular organization, i.e. the state of
aggregation of multiple SP-D molecules in solution and the
activity of HLE. Our results are similar to those observed for
surfactant protein A (SP-A), a closely related lung collectin
[19]. Degradation of SP-A by activated neutrophils was
prevented by the in vitro addition of calcium [19].
Although in previous studies it appeared that calcium
was completely protective for the proteolysis of native SP-D
by HLE [10], this effect was surpassed by an increase in
elastase concentration. Instead of 1 AM (1 U/ml), our
experiments were done with 0.5, 5 and 50 U/ml.
The activity of HLE in BAL fluid or in sputum from
patients with neutrophil-dominated inflammatory lung dis-
eases are well in the range that may allow limited proteol-
ysis of SP-D in vivo. In a previous study in patients with
cystic fibrosis, we found up to 19 U/ml in BALs [11] not
respecting the dilution of lavage fluid compared to the
epithelial lining fluid. Others have detected similar and
even much higher activities in CF lavages [12,20] or CF
sputum [21]. Free elastolytic activity is present in a variety
of lung diseases and is involved in their pathogenesis [22].
These data and the results of this study suggest that
proteolytically degraded SP-D may be expected in patients
with inflammatory lung diseases, but this has not been
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elastase activity in the BAL fluid indicated decreased SP-D
bands in some, but not in all subjects (own unpublished
results). In contrast, lung diseases without significant neu-
trophilic inflammation in BAL fluid are not expected to
exhibit degraded SP-D. This conclusion is in agreement
with previous results in children with gastroesophageal
reflux, chronic lung disease, but lack of neutrophils in
BAL fluid. Only a very small fraction of the SP-D was
found at about 36–38 kDa [23].
A loss of the biological activity of the CRD by a limited
proteolysis of the SP-D, as demonstrated in this study, may
have significant implications for a large range of pathways,
including SP-D mediated chemotaxis of monocytes and
neutrophils [24], opsonization, enhanced internalization and
killing of bacteria, viruses and fungi by leukocytes [25], the
inhibition of oxidant induced neutrophil apoptosis and acti-
vation of P-38 [26], the inhibition of T-cell proliferation [27],
and antigen-presentation by dendritic cells [28]. Further
functional properties of SP-D that are not dependent on the
CRD may still be conserved or indirectly altered.
In summary, SP-D dodecamers and higher-structured
multimers can be proteolytically degraded to a limited
extent at concentrations of HLE existing during neutrophilic
inflammatory lung diseases. Calcium at physiologic con-
centration is only partially protective and may be overcome
by increased HLE concentrations or prolonged exposure to
the enzyme. The primary target for the serine protease HLE
is the CRD of the SP-D evoking its loss of function. These
mechanisms are likely to be involved in the impairment of
local host defense mechanisms during neutrophilic inflam-
matory lung diseases.References
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